1. Scrip
  2. >>Drug Pricing

Teva Launches Generic EpiPen At Same Price As Mylan's Generic

 
• By Jessica Merrill

Teva's epinephrine will be the first alternative to branded and authorized generics made by Mylan, but the wholesale acquisition cost of $300 for a two-pack won't be lower.

Down arrow on pavement

Teva Pharmaceutical Industries Ltd. is launching the first alternative version of the emergency allergy medicine EpiPen (epinephrine) outside of Mylan's brand and authorized generics, but the cost will be the same. The wholesale acquisition cost of Teva's generic is $300 for a two-pack, the same WAC as Mylan's authorized generic.

It looks like it might take more competition on the market to lower the price, or perhaps competitive rebating, though...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

More from Scrip

Citeline Japan Awards 2025 - Enter Now!

 
• By Ian Haydock and Lisa Takagi

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.